Evidence map›Paper›PMID 39981247›Full record

ArticleFrontiers in immunology2025

Unleashing the potential of a low CpG

Jianyao Zeng, Yan Sun, Yuan Fang, Xiaodie Wang, Qian Huang, Pingjing Zhang, Meiqi Shao, Pei Wang, Jingbo Cheng, Meng Di and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jianyao Zeng *School of Medicine, Shanghai University, Shanghai, China.
Yan Sun *School of Medicine, Shanghai University, Shanghai, China.
Yuan Fang *Innovative Drugs Business Group, Shanghai Cell Therapy Group, Shanghai, China.
Xiaodie WangSchool of Medicine, Shanghai University, Shanghai, China.
Qian HuangInnovative Drugs Business Group, Shanghai Cell Therapy Group, Shanghai, China.
Pingjing ZhangInnovative Drugs Business Group, Shanghai Cell Therapy Group, Shanghai, China.
Meiqi ShaoInnovative Drugs Business Group, Shanghai Cell Therapy Group, Shanghai, China.
Pei WangInnovative Drugs Business Group, Shanghai Cell Therapy Group, Shanghai, China.
Jingbo ChengInnovative Drugs Business Group, Shanghai Cell Therapy Group, Shanghai, China.
Meng DiSchool of Medicine, Shanghai University, Shanghai, China.
Tao LiuInnovative Drugs Business Group, Shanghai Cell Therapy Group, Shanghai, China.
Qijun QianSchool of Medicine, Shanghai University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To date, the non-viral vector Chimeric Antigen Receptor (CAR) T cell preparation platform, exemplified by transposons, has demonstrated significant potential in tumor immunotherapy and yielded positive results in multiple clinical trials. Nonetheless, non-methylated CpG sequences within plasmid DNA can elicit an inflammatory response via Toll-like receptor 9 (TLR9) during CAR-T cell preparation, adversely affecting transgene expression. Additionally, de novo DNA methylation programs promote T cell exhaustion, which poses a significant limitation for CAR-T cell therapy applications. Methods: High-throughput liquid protein chip and CBA analyses were utilized to determine the expression levels of inflammatory factors. Flow cytometry and luciferase reporter assays were employed for mutation screening. BALB/c mice and M-NSG mice were used to evaluate the inflammatory response and efficacy of LCG CAR-T Results: In this study, we modified the newly discovered Passer (JL) transposon to construct a low-CpG content transposon for CAR-T cell (LCG CAR-T cell) preparation. Conclusions: Collectively, our results demonstrate the high safety and efficacy of non-viral, low CpG Passer transposon CAR-T cells, offering new avenues for improving CAR-T cell efficacy while minimizing

Indexed as

CpG IslandsDNA Transposable ElementsImmunotherapy, AdoptiveReceptors, Chimeric AntigenAnimalsCell Line, TumorDNA MethylationFemaleHumansLymphocytes, Tumor-InfiltratingMiceMice, Inbred BALB CDNA Transposable ElementsReceptors, Chimeric Antigenchimeric antigen receptor T cellCpG motifinflammationmethylationtransposon

Identifiers

PMID39981247
PMCPMC11840574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.